# Drug-Safety and Pharmaceutical-Quality Data Source Registry

## Drug Safety & QC Evidence Mapping Foundation

### Biotech Learnship – Test 1

**Prepared by:** Shravani Jambhulkar  
**Academic Background:** Fourth-Year B.Pharmacy Student  
**Project Area:** Pharmacovigilance, Drug Safety, Laboratory QC and Evidence Validation

---

# 1. Purpose of This Registry

This registry documents credible public sources that can provide information relevant to:

- Pharmacovigilance.
- Adverse events.
- Adverse drug reactions.
- Drug-safety signals.
- Product labeling and safety information.
- Clinical research.
- Scientific literature.
- Pharmaceutical quality.
- Regulatory guidance.
- Laboratory and QC evidence.

The purpose is not to treat every public source as equally authoritative.

Different sources provide different types of evidence. Therefore, future users of this evidence framework should consider:

```text
Source
+
Organisation
+
Evidence Type
+
Data Quality
+
Limitations
+
Validation Status
+
Evidence Provenance
+
Human Review
```

before using information for further analysis.

---

# 2. Source Comparison Summary

| No. | Source | Organisation | Main Use |
|---|---|---|---|
| 1 | FDA FAERS | U.S. Food and Drug Administration | Post-marketing adverse event reporting |
| 2 | OpenFDA | U.S. Food and Drug Administration | Structured access to selected FDA datasets |
| 3 | DailyMed | U.S. National Library of Medicine | Official drug labeling information |
| 4 | FDA Drug Safety Communications | U.S. Food and Drug Administration | Important drug-safety information and regulatory communications |
| 5 | WHO Pharmacovigilance Resources | World Health Organization | Global pharmacovigilance guidance and safety principles |
| 6 | PubMed | U.S. National Library of Medicine / NIH | Scientific and biomedical literature |
| 7 | ClinicalTrials.gov | U.S. National Library of Medicine / NIH | Clinical study and trial information |
| 8 | EMA Safety Information | European Medicines Agency | European medicine safety and regulatory information |
| 9 | ICH Guidelines | International Council for Harmonisation | International quality, safety and regulatory guidelines |

---

# 3. FDA FAERS

## Source Name

FDA Adverse Event Reporting System (FAERS)

## Organisation

U.S. Food and Drug Administration (FDA)

## Purpose

FAERS is used to collect and support the analysis of reports of adverse events, medication errors, and other safety-related information involving FDA-regulated medical products.

It supports post-marketing pharmacovigilance and can contribute to the identification of possible safety concerns.

## Information Available

FAERS may contain information related to:

- Suspected adverse events.
- Drug or product information.
- Reported reactions.
- Outcomes.
- Reporter information categories.
- Patient demographic information where available in the public data.
- Concomitant medicines.
- Medication errors.
- Report dates and case-related information.

## Data Format / Access Method

Information may be available through:

- FDA public FAERS data files.
- Downloadable datasets.
- Quarterly data files.
- Public data access tools.
- OpenFDA APIs for selected structured access.

## Public Accessibility

Yes. Publicly accessible data and information are available.

## Evidence Quality

FAERS is an important pharmacovigilance data source because it contains large numbers of real-world reports.

However, individual reports vary in completeness and reliability.

FAERS reports should be treated as:

```text
Safety Evidence / Safety Reports
```

and not as automatic proof that a specific drug caused a reported event.

## Known Limitations

Important limitations may include:

- Underreporting.
- Duplicate reports.
- Incomplete information.
- Reporting bias.
- Missing clinical details.
- Lack of complete information about alternative causes.
- Lack of a direct denominator for the total number of exposed patients.
- A report does not independently prove causality.

Therefore:

```text
FAERS Report
≠
Confirmed Drug Causality
```

## Important Terminology

- Adverse event.
- Adverse reaction.
- Safety signal.
- Case report.
- Serious outcome.
- Medication error.
- Signal detection.
- Post-marketing surveillance.

## Potential BHIV Use

Potential uses include:

- Identifying structured safety observations.
- Building evidence records.
- Detecting possible repeated reporting patterns.
- Supporting safety-signal research.
- Developing data-cleaning and duplicate-detection workflows.
- Training future systems to distinguish reports from confirmed conclusions.

## Suitable for AI/Data Science Processing

Yes, with appropriate data cleaning, validation, provenance tracking, duplicate handling, and human scientific review.

## Overall Assessment

**High value for post-marketing safety research, but individual reports must not be treated as proof of causality.**

---

# 4. OpenFDA

## Source Name

OpenFDA

## Organisation

U.S. Food and Drug Administration (FDA)

## Purpose

OpenFDA provides structured access to selected FDA public datasets through application programming interfaces (APIs) and downloadable data.

It can make certain FDA datasets easier for software and data-analysis systems to access and process.

## Information Available

Depending on the available dataset and endpoint, information may include:

- Adverse-event data.
- Drug labeling information.
- Drug recall information.
- Medical product information.
- Structured FDA data fields.

## Data Format / Access Method

Access may include:

- APIs.
- JSON-based responses.
- Structured machine-readable data.
- Query-based access.

## Public Accessibility

Yes.

## Evidence Quality

The quality depends on the original source dataset.

OpenFDA is primarily an access and data-structure platform. The underlying data source should always be identified.

For example:

```text
OpenFDA Access Layer
        ↓
Underlying FDA Dataset
        ↓
Source-Specific Limitations
```

## Known Limitations

- Quality depends on the underlying dataset.
- Not all information is complete or standardized.
- API results may require careful interpretation.
- Data cleaning may be necessary.
- Access to structured data does not make the information automatically clinically validated.
- Source limitations remain applicable.

## Important Terminology

- API.
- Endpoint.
- JSON.
- Structured data.
- Query.
- Dataset.
- Machine-readable data.

## Potential BHIV Use

Potential uses include:

- Automated evidence collection.
- Structured data processing.
- Building future data pipelines.
- Searching and filtering public information.
- Creating reproducible data workflows.
- Supporting AI/Data Science prototypes.

## Suitable for AI/Data Science Processing

Yes. It is particularly suitable for structured software and data-analysis workflows.

However:

```text
Machine-Readable
≠
Scientifically Proven
```

The quality and limitations of the original evidence must still be considered.

## Overall Assessment

**Highly useful for software, AI/Data Science, and structured data processing when used with source-aware validation.**

---

# 5. DailyMed

## Source Name

DailyMed

## Organisation

U.S. National Library of Medicine (NLM), National Institutes of Health (NIH)

## Purpose

DailyMed provides access to drug-labeling information for healthcare products.

It is useful for reviewing official product information and known safety-related information.

## Information Available

Information may include:

- Product name.
- Active ingredients.
- Dosage forms.
- Indications.
- Warnings and precautions.
- Contraindications.
- Adverse reactions.
- Drug interactions.
- Dosage information.
- Product labeling sections.
- Manufacturer or labeler information.

## Data Format / Access Method

Information may be accessed through:

- Web pages.
- Structured drug-label information.
- Standardized labeling formats.
- Downloadable or machine-readable resources where available.

## Public Accessibility

Yes.

## Evidence Quality

DailyMed is a highly useful source for structured and official product-labeling information.

It is particularly useful for determining whether a reaction or safety concern is already described in the available product information.

## Known Limitations

- Product labeling may not contain every possible safety concern.
- Absence of an event from a label does not prove that the event is caused by a drug.
- Label information may change over time.
- A current label should be checked when date-specific information is important.
- Product labeling should not be interpreted as a complete causality database.

## Important Terminology

- Prescribing information.
- Adverse reactions.
- Warnings.
- Precautions.
- Contraindications.
- Drug interactions.
- Labeling.

## Potential BHIV Use

Potential uses include:

- Drug/product identification.
- Checking known adverse reactions.
- Supporting expected versus unexpected reaction assessment.
- Building structured safety-information fields.
- Linking evidence records to product-label information.

## Suitable for AI/Data Science Processing

Yes, especially for:

- Text extraction.
- Terminology mapping.
- Structured labeling analysis.
- Drug-safety knowledge systems.

Human review is still required for interpretation.

## Overall Assessment

**High-quality source for official drug-labeling and known safety information.**

---

# 6. FDA Drug Safety Communications

## Source Name

FDA Drug Safety Communications

## Organisation

U.S. Food and Drug Administration (FDA)

## Purpose

FDA Drug Safety Communications provide important safety information about medicines and other regulated products.

These communications may describe newly identified safety concerns, warnings, label changes, recommendations for risk reduction, or other important regulatory safety information.

## Information Available

Information may include:

- Newly identified safety concerns.
- Regulatory safety updates.
- Label changes.
- Warnings.
- Ongoing safety reviews.
- Drug-specific safety information.
- Information about known risks.

## Data Format / Access Method

Information is generally available through:

- Official FDA web pages.
- Drug-safety communication notices.
- Safety updates.
- Regulatory publications.

## Public Accessibility

Yes.

## Evidence Quality

This is a high-authority regulatory source.

FDA safety communications are useful because they represent reviewed regulatory safety information.

However, individual communications should still be read in their full context.

## Known Limitations

- Communications are focused on specific issues and may not provide complete information about all safety aspects of a medicine.
- Historical communications may be superseded by newer information.
- Information may need to be reviewed with the latest labeling and regulatory updates.
- A safety communication is not a substitute for complete scientific evidence review.

## Important Terminology

- Drug safety communication.
- Safety concern.
- Label change.
- Warning.
- Risk.
- Regulatory review.

## Potential BHIV Use

Potential uses include:

- High-priority evidence sources.
- Regulatory safety tracking.
- Safety-signal follow-up.
- Building evidence-provenance records.
- Identifying regulatory-confirmed or actively reviewed concerns.

## Suitable for AI/Data Science Processing

Partially suitable.

The information is valuable but may require:

- Text processing.
- Manual interpretation.
- Date tracking.
- Document classification.
- Human review.

## Overall Assessment

**High-authority regulatory evidence source for important safety communications.**

---

# 7. WHO Pharmacovigilance Resources

## Source Name

World Health Organization Pharmacovigilance Resources

## Organisation

World Health Organization (WHO)

## Purpose

WHO provides guidance, resources, and international information related to medicine safety and pharmacovigilance.

These resources help support understanding of how adverse effects and medicine-related problems can be monitored and assessed.

## Information Available

Information may include:

- Pharmacovigilance principles.
- Medicine-safety guidance.
- Adverse-event reporting concepts.
- Global medicine-safety information.
- Public-health guidance.
- Training and educational materials.

## Data Format / Access Method

Information may be available through:

- Official web resources.
- Guidance documents.
- Publications.
- Reports.
- Training materials.

## Public Accessibility

Many WHO pharmacovigilance resources are publicly accessible.

Access to some global pharmacovigilance databases may be restricted or managed through appropriate authorized systems.

## Evidence Quality

WHO is a highly credible international public-health organization.

Its guidance and reference materials are valuable for understanding pharmacovigilance concepts and global safety principles.

## Known Limitations

- Not all WHO-related safety databases are openly available as raw data.
- Some resources are guidance documents rather than patient-level or case-level evidence.
- International terminology and reporting practices may vary.
- Access and use of specific databases may be subject to additional requirements.

## Important Terminology

- Pharmacovigilance.
- Adverse drug reaction.
- Adverse event.
- Signal.
- Post-marketing surveillance.
- Medicine safety.

## Potential BHIV Use

Potential uses include:

- Developing pharmacovigilance concepts.
- Creating evidence-validation frameworks.
- Supporting standardized safety workflows.
- Training future researchers.
- Understanding global safety principles.

## Suitable for AI/Data Science Processing

Partially suitable.

Public documents may be processed for knowledge extraction, but restricted databases cannot automatically be assumed to be publicly available for AI/Data Science use.

## Overall Assessment

**High-authority international source for pharmacovigilance concepts and global medicine-safety guidance.**

---

# 8. PubMed

## Source Name

PubMed

## Organisation

U.S. National Library of Medicine (NLM), National Institutes of Health (NIH)

## Purpose

PubMed is a major database for searching biomedical and scientific literature.

It is useful for identifying published research related to:

- Drug safety.
- Adverse drug reactions.
- Pharmacovigilance.
- Laboratory methods.
- Pharmaceutical quality.
- Clinical research.
- Systematic reviews.

## Information Available

PubMed records may include:

- Article titles.
- Abstracts.
- Author information.
- Journal information.
- Publication dates.
- Medical subject indexing.
- Links to full text where available.

## Data Format / Access Method

Access may include:

- Web search.
- Structured bibliographic records.
- Search APIs and tools.
- Downloadable citation information.

## Public Accessibility

Search and bibliographic information are publicly accessible.

However, not every full research article is freely available.

## Evidence Quality

PubMed is a highly valuable literature-discovery source.

However:

```text
Indexed in PubMed
≠
Every Article Has the Same Evidence Quality
```

The quality depends on:

- Study design.
- Sample size.
- Methodology.
- Bias.
- Relevance.
- Reproducibility.
- Peer-review quality.
- Limitations.

## Known Limitations

- Search results may include studies with different levels of evidence.
- Publication bias may exist.
- Some full texts may not be freely accessible.
- Search results require critical appraisal.
- A single publication may not establish a definitive scientific conclusion.

## Important Terminology

- Abstract.
- Peer review.
- Case report.
- Clinical study.
- Systematic review.
- Meta-analysis.
- Publication bias.

## Potential BHIV Use

Potential uses include:

- Literature evidence discovery.
- Finding supporting studies.
- Signal evaluation.
- Drug-safety research.
- QC and analytical-method research.
- Evidence mapping.

## Suitable for AI/Data Science Processing

Yes, particularly for:

- Bibliographic analysis.
- Literature classification.
- Evidence retrieval.
- Abstract analysis.
- Terminology mapping.

Full scientific interpretation still requires appropriate human review.

## Overall Assessment

**High-value literature discovery source, but individual studies require critical appraisal.**

---

# 9. ClinicalTrials.gov

## Source Name

ClinicalTrials.gov

## Organisation

U.S. National Library of Medicine (NLM), National Institutes of Health (NIH)

## Purpose

ClinicalTrials.gov provides information about registered clinical studies.

It can help researchers identify ongoing, completed, terminated, or other registered clinical research studies.

## Information Available

Records may include:

- Study title.
- Study design.
- Intervention.
- Condition studied.
- Eligibility criteria.
- Outcome measures.
- Study status.
- Sponsor information.
- Study dates.
- Results information where available.
- Adverse-event information for some posted results.

## Data Format / Access Method

Access may include:

- Public website search.
- Structured records.
- Downloadable data.
- API or machine-readable access where available.

## Public Accessibility

Yes.

## Evidence Quality

ClinicalTrials.gov is a valuable source for identifying registered studies and available study information.

However, the existence of a registered study does not automatically mean that the intervention is proven safe or effective.

## Known Limitations

- Not all studies have posted results.
- Some records may be updated over time.
- Reported information may vary in completeness.
- Registry information should be interpreted with the associated study design and results.
- A registered trial does not independently prove causality.

## Important Terminology

- Clinical study.
- Intervention.
- Primary outcome.
- Secondary outcome.
- Enrollment.
- Study status.
- Adverse event.
- Serious adverse event.

## Potential BHIV Use

Potential uses include:

- Identifying clinical evidence.
- Linking safety evidence to study information.
- Researching drug exposure and reported outcomes.
- Comparing post-marketing observations with clinical-study information.

## Suitable for AI/Data Science Processing

Yes. Structured study information can support:

- Data extraction.
- Study classification.
- Evidence mapping.
- Metadata analysis.

Appropriate scientific interpretation is still required.

## Overall Assessment

**High-value structured source for registered clinical-study information and available results.**

---

# 10. European Medicines Agency Safety Information

## Source Name

European Medicines Agency (EMA) Safety Information

## Organisation

European Medicines Agency (EMA)

## Purpose

EMA provides regulatory information related to medicines authorized and monitored within the European regulatory system.

Its resources may include medicine safety information and regulatory safety updates.

## Information Available

Depending on the medicine and available documents, information may include:

- Medicine safety information.
- Product information.
- Risk information.
- Regulatory actions.
- Safety communications.
- Assessment information.
- Pharmacovigilance-related updates.

## Data Format / Access Method

Information may be available through:

- Official EMA web pages.
- Product information documents.
- Regulatory documents.
- Public safety updates.
- Downloadable publications.

## Public Accessibility

Many EMA safety and medicine-information resources are publicly accessible.

## Evidence Quality

EMA is a high-authority regulatory organization.

Its safety information is particularly valuable for reviewed European regulatory information.

## Known Limitations

- Regulatory information may be specific to the European regulatory context.
- Information may change over time.
- Different products may have different document availability.
- Older documents may need to be compared with current information.
- Public information may require expert interpretation.

## Important Terminology

- Pharmacovigilance.
- Product information.
- Risk management.
- Safety signal.
- Adverse reaction.
- Regulatory assessment.

## Potential BHIV Use

Potential uses include:

- International regulatory evidence mapping.
- Safety-information comparison.
- Product safety review.
- Risk and regulatory tracking.
- Building evidence provenance.

## Suitable for AI/Data Science Processing

Partially suitable.

Structured and downloadable documents may be processed, but text interpretation and regulatory context require human review.

## Overall Assessment

**High-authority regulatory source for European medicine safety information.**

---

# 11. International Council for Harmonisation (ICH) Guidelines

## Source Name

International Council for Harmonisation (ICH) Guidelines

## Organisation

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

## Purpose

ICH develops internationally harmonized guidelines related to:

- Quality.
- Safety.
- Efficacy.
- Multidisciplinary pharmaceutical and regulatory topics.

ICH guidance is important for understanding internationally recognized principles and expectations.

## Information Available

Relevant information may include:

- Pharmaceutical quality guidelines.
- Stability principles.
- Analytical and quality principles.
- Safety guidelines.
- Clinical safety reporting concepts.
- Data and regulatory harmonization guidance.

## Data Format / Access Method

Information is generally available through:

- Official guideline documents.
- Downloadable publications.
- Official web resources.

## Public Accessibility

Yes, official guideline information is publicly accessible.

## Evidence Quality

ICH guidelines are highly authoritative reference documents for internationally harmonized pharmaceutical and regulatory principles.

They are particularly useful for establishing structured concepts and expectations.

## Known Limitations

- Guidelines are not individual patient case reports.
- They do not directly prove causality for specific drug-event cases.
- Implementation may depend on local regulations and applicable requirements.
- Guidelines must be interpreted in the correct regulatory and scientific context.

## Important Terminology

- Quality.
- Safety.
- Efficacy.
- Good clinical practice.
- Pharmacovigilance.
- Data standards.
- Stability.
- Analytical validation.

## Potential BHIV Use

Potential uses include:

- Developing evidence-validation principles.
- Creating structured QC models.
- Supporting documentation standards.
- Understanding internationally harmonized quality concepts.
- Designing future data models.

## Suitable for AI/Data Science Processing

Yes, primarily for:

- Knowledge extraction.
- Guideline classification.
- Document search.
- Terminology mapping.
- Rule-support systems.

However, AI systems should not independently interpret guidelines as substitutes for expert regulatory judgement.

## Overall Assessment

**Very high-value source for pharmaceutical quality and internationally harmonized regulatory principles.**

---

# 12. Source Authority and Evidence Hierarchy

The sources in this registry should not be treated as interchangeable.

A simplified comparison is:

| Source Type | Example | Main Strength | Main Limitation |
|---|---|---|---|
| Regulatory safety database | FAERS | Large post-marketing safety-report collection | Reports do not independently prove causality |
| Structured data platform | OpenFDA | Machine-readable access | Depends on underlying source data |
| Official product information | DailyMed | Product-label safety information | Does not contain every possible safety concern |
| Regulatory communication | FDA Safety Communications | High-authority safety updates | Usually issue-specific |
| International guidance | WHO | Global pharmacovigilance principles | Not always raw case-level data |
| Scientific literature | PubMed | Research evidence discovery | Individual studies require critical appraisal |
| Clinical study registry | ClinicalTrials.gov | Structured study information | Registry data do not automatically prove conclusions |
| Regulatory authority | EMA | Reviewed European medicine safety information | Regulatory context may differ by region |
| Harmonized guidelines | ICH | International quality and regulatory principles | Not case-specific evidence |

---

# 13. Evidence Source Validation Approach

Before information from a source is entered into a future evidence system, the following questions should be considered:

```text
1. What is the original source?

2. Who produced the information?

3. What type of evidence is it?

4. When was it published or updated?

5. Is the information complete?

6. Is the information traceable?

7. Are there known limitations?

8. Is the information a report, a signal, a study finding, a laboratory result, or regulatory information?

9. Has the information been independently reviewed or validated?

10. Does the record require human scientific review?
```

A simplified validation workflow is:

```text
Source Identified
        ↓
Organisation Checked
        ↓
Evidence Type Classified
        ↓
Access Method Recorded
        ↓
Limitations Recorded
        ↓
Provenance Preserved
        ↓
Validation Status Assigned
        ↓
Human Review if Required
```

---

# 14. Recommended Evidence Fields for Future AI/Data Science Use

Future systems using these sources should preserve fields such as:

- Evidence ID.
- Source name.
- Source organisation.
- Source type.
- Evidence type.
- Drug/product identifier.
- Observation.
- Date.
- Data access method.
- Supporting documentation.
- Evidence provenance.
- Evidence quality.
- Validation status.
- Known limitations.
- Human-review flag.

A possible data structure is:

```text
Evidence Record
        ↓
Evidence ID
        ↓
Source and Organisation
        ↓
Drug/Product
        ↓
Evidence Type
        ↓
Observation
        ↓
Supporting Documentation
        ↓
Provenance
        ↓
Evidence Quality
        ↓
Validation Status
        ↓
Limitations
        ↓
Human Review
```

---

# 15. AI/Data Science Suitability Summary

| Source | AI/DS Suitability | Reason |
|---|---|---|
| FDA FAERS | High with validation | Large structured safety-report data, but requires duplicate and quality checks |
| OpenFDA | High | API and machine-readable structured data |
| DailyMed | High | Structured product-label information |
| FDA Drug Safety Communications | Moderate | Valuable information but may require text processing and context review |
| WHO Resources | Moderate | High-quality guidance, but some data resources may have restricted access |
| PubMed | High for literature analysis | Structured bibliographic information and searchable research evidence |
| ClinicalTrials.gov | High | Structured clinical-study metadata and available results |
| EMA | Moderate to High | Valuable regulatory documents and safety information, requiring contextual interpretation |
| ICH Guidelines | Moderate to High | Useful for knowledge extraction and structured quality/regulatory concepts |

---

# 16. Important Limitations for Future Use

The following principles must be followed when using public drug-safety information:

```text
Publicly Available
≠
Automatically High-Quality for Every Purpose
```

```text
Reported Event
≠
Confirmed Adverse Drug Reaction
```

```text
Safety Signal
≠
Proof of Causality
```

```text
Structured Data
≠
Automatic Scientific Conclusion
```

```text
AI Processing
≠
Replacement for Human Scientific Review
```

Public evidence should be evaluated according to:

- Source credibility.
- Evidence type.
- Completeness.
- Traceability.
- Limitations.
- Date and version.
- Validation status.
- Relevance to the research question.

---

# 17. Recommended BHIV Evidence-Source Workflow

The following workflow is proposed for future BHIV AI/Data Science and pharmacy teams:

```text
Public / Regulatory / Scientific Source
        ↓
Source Identification
        ↓
Evidence Extraction
        ↓
Evidence Record Creation
        ↓
Provenance Recording
        ↓
Data Validation
        ↓
Evidence Quality Review
        ↓
Duplicate / Conflict Check
        ↓
Validation Status Assignment
        ↓
Human Review Flag
        ↓
Structured Output for Future AI/DS Use
```

The purpose of this workflow is to organize evidence without making unsupported clinical or scientific conclusions.

---

# 18. Conclusion

This registry identifies multiple credible sources relevant to pharmacovigilance, drug safety, pharmaceutical quality, laboratory QC, and evidence validation.

Each source has different strengths, purposes, data formats, and limitations.

The most important learning from this source registry is that future evidence systems should not simply collect information from public databases.

They should also record:

```text
Where the evidence came from
        +
What type of evidence it is
        +
How reliable and complete it is
        +
What limitations it has
        +
Whether validation has occurred
        +
Whether human review is required
```

The recommended foundation for future BHIV AI/Data Science systems is therefore:

```text
Credible Source
        ↓
Evidence Extraction
        ↓
Evidence Provenance
        ↓
Data Validation
        ↓
Evidence Quality Assessment
        ↓
Limitations Recorded
        ↓
Human Review
        ↓
Structured and Traceable Output
```

The final principle is:

```text
A credible source can provide valuable evidence,

but evidence still requires context, validation,
documentation, and appropriate human review.
```